Winfield Associates’s Bristol-Myers Squibb BMY Stock Holding History

Winfield Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-410	Closed	-$26K	–	184
2017 Q4	$26K	Hold	410	–	–	0.01%	266
2017 Q3	$26K	Hold	410	–	–	0.01%	256
2017 Q2	$23K	Buy	410 +120	+41%	+$6.53K	0.01%	265
2017 Q1	$15K	Sell	290 -195	-40%	-$10.7K	0.01%	311
2016 Q4	$28K	Sell	485 -115	-19%	-$6.29K	0.02%	225
2016 Q3	$32K	Sell	600 -330	-35%	-$21.2K	0.02%	209
2016 Q2	$68K	Buy	930 +290	+45%	+$20.5K	0.04%	154
2016 Q1	$41K	Sell	640 -170	-21%	-$10.7K	0.03%	187
2015 Q4	$56K	Hold	810	–	–	0.04%	149
2015 Q3	$48K	Hold	810	–	–	0.04%	161
2015 Q2	$54K	Hold	810	–	–	0.04%	158
2015 Q1	$52K	Buy	810 +310	+62%	+$19.4K	0.04%	160
2014 Q4	$30K	Hold	500	–	–	0.02%	183
2014 Q3	$26K	Hold	500	–	–	0.02%	187
2014 Q2	$24K	Hold	500	–	–	0.02%	204
2014 Q1	$26K	Buy	+500	New	+$26.6K	0.02%	186

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winfield Associates's BMY Position: Q1 2018 in Review

Winfield Associates sold out of Bristol-Myers Squibb (BMY) in Q1 2018, closing a stake of 410 shares — an estimated $26K sold.

Winfield Associates first reported a position in BMY in Q1 2014 and held it in 16 quarters. The position peaked at $68K in Q2 2016. 1,747 funds tracked by Wall St. Rank hold BMY as of Q1 2018.

Winfield Associates reported no remaining Bristol-Myers Squibb position as of Q1 2018 after selling out during the quarter.
Winfield Associates sold 410 Bristol-Myers Squibb shares in Q1 2018, an estimated $26K.
Winfield Associates first reported a position in Bristol-Myers Squibb in Q1 2014 and held it in 16 quarters.
Winfield Associates's Bristol-Myers Squibb position peaked at $68K in Q2 2016.
1,747 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.